Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL D50 versus HY PAM 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL D50 versus HY PAM 25.
ALDORIL D50 vs HY-PAM "25"
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Hydroxyzine pamoate is a piperazine antihistamine that acts as a histamine H1-receptor antagonist, thereby suppressing histamine-mediated responses in the skin and mucous membranes. Additionally, it exhibits anxiolytic and sedative properties through central nervous system depression via inhibition of subcortical regions.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
25 mg orally once daily, preferably at bedtime, for short-term treatment of insomnia.
None Documented
None Documented
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Terminal elimination half-life 6-8 hours in healthy adults; prolonged to 12-18 hours in renal impairment (CrCl <30 mL/min) and in elderly patients.
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
Primarily renal (60-70% unchanged drug), with 30-40% biliary/fecal elimination as metabolites.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination